NASDAQ · Biotechnology

PYXS (PYXS) Stock

$3.73 -0.53% NASDAQ: PYXS Healthcare

Valuation

MetricValue
Price$3.73
Market Cap$236.32M
P/E Ratio-1.56
P/B Ratio2.39
P/S Ratio9.14
EPS (TTM)$-1.28
52-Week High$5.55
52-Week Low$0.97
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-150.94%
ROA-86.96%
ROCE-155.56%
Gross Margin-600.00%
Operating Margin-600.00%
Net Margin-5.90%
Debt/Equity0.58
Current Ratio3.43

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$16.0M$14.0M
Operating Profit$-70.0M$-123.0M$-82.0M$-89.0M$-84.0M
Net Profit$-76.0M$-121.0M$-74.0M$-77.0M$-80.0M
EPS$-2.53$-3.57$-1.85$-1.32$-1.28
Op Margin———-554.1%-609.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$280.0M$211.0M$174.0M$157.0M$92.0M
Total Liabilities$19.0M$51.0M$48.0M$36.0M$38.0M
Cash$275.0M$179.0M$10.0M$19.0M$15.0M
Borrowings$0$19.0M$21.0M$20.0M$19.0M

Latest News

Pyxis Oncology Secures Up to $114 Million Private Placement MT Newswires · Jun 30, 2026 Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones GlobeNewswire · Jun 30, 2026 Analysts See Nearly 3X Upside in Pyxis Oncology (PYXS) Insider Monkey · Jun 10, 2026 Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones GlobeNewswire · May 14, 2026 Pyxis Oncology to Participate in Upcoming Investor Conferences GlobeNewswire · May 13, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-35.0M$-89.0M$-71.0M$-58.0M$-64.0M
Investing Cash Flow$-1.0M$-13.0M$-112.0M$8.0M$59.0M
Financing Cash Flow$0$0$0$0$0
Net Cash Flow$268.0M$-96.0M$-170.0M$10.0M$-4.0M
Free Cash Flow$-36.0M$-96.0M$-77.0M$-58.0M$-64.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-52.86%
Quick Ratio2.76
Interest Coverage—
Return 1Y92.44%
Return 3Y-13.58%
Return 5Y—

Ownership

Insiders Held13.60%
Institutions Held42.45%
Institutions Float Held49.13%
Institutional HolderSharesReport Date
Pfizer Inc7,032,7702026-03-31
Laurion Capital Management, LP4,997,3332026-03-31
GordonMD Global Investments LP4,121,8702026-03-31
Vanguard Capital Management LLC2,033,5102026-03-31
Palo Alto Investors Lp1,010,5102026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVIR $4.75 +1.06% -2.13 $380.13M 0.00%
CRBU $1.65 +0.61% -1.25 $163.65M 0.00%
ENTA $12.61 -0.94% -6.04 $366.68M 0.00%
FHTXFoghorn Therapeutics Inc. $5.20 +7.22% -4.15 $305.31M 0.00%
HUMA $0.66 -1.79% -4.19 $110.81M 0.00%

About PYXS

PYXS is led by CEO Thomas Civik, employs 44 people, headquartered in US, publicly traded since 2021.

PYXS stock trades at $3.73 with a market capitalization of $236.32M. The stock is valued at a price-to-earnings (P/E) ratio of -1.56, price-to-book of 2.39, price-to-sales of 9.14. Over the past 52 weeks the stock has ranged between $0.97 and $5.55, and currently trades 32.8% below its 52-week high.

On profitability, PYXS generates a return on equity (ROE) of -150.94%, return on capital employed of -155.56%, an operating margin of -600.00%, a net profit margin of -5.90%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides